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Abstract
Objective To obtain precise estimates of age, haematoma volume, secondary haematoma expansion (HE) and mortality 
for patients with intracerebral haemorrhage (ICH) taking oral anticoagulants [Vitamin K antagonists (VKA-ICH) or non-
Vitamin K antagonist oral anticoagulants (NOAC-ICH)] and those not taking oral anticoagulants (non-OAC ICH) at ICH 
symptom onset.
Methods We conducted a systematic review and meta-analysis of studies comparing VKA-ICH or NOAC-ICH or both with 
non-OAC ICH. Primary outcomes were haematoma volume (in ml), HE, and mortality (in-hospital and 3-month). We cal-
culated odds ratios (ORs) using the Mantel–Haenszel random-effects method and corresponding 95% confidence intervals 
(95%CI) and determined the mean ICH volume difference.
Results We identified 19 studies including data from 16,546 patients with VKA-ICH and 128,561 patients with non-OAC 
ICH. Only 2 studies reported data on 4943 patients with NOAC-ICH. Patients with VKA-ICH were significantly older than 
patients with non-OAC ICH (mean age difference: 5.55 years, 95%CI 4.03–7.07, p < 0.0001, I2 = 92%, p < 0.001). Haema-
toma volume was significantly larger in VKA-ICH with a mean difference of 9.66 ml (95%CI 6.24–13.07 ml, p < 0.00001; 
I2 = 42%, p = 0.05). HE occurred significantly more often in VKA-ICH (OR 2.96, 95%CI 1.74–4.97, p < 0.00001; I2 = 65%). 
VKA-ICH was associated with significantly higher in-hospital mortality (VKA-ICH: 32.8% vs. non-OAC ICH: 22.4%; OR 
1.83, 95%CI 1.61–2.07, p < 0.00001, I2 = 20%, p = 0.27) and 3-month mortality (VKA-ICH: 47.1% vs. non-OAC ICH: 25.5%; 
OR 2.24, 95%CI 1.52–3.31, p < 0.00001, I2 = 71%, p = 0.001). We did not find sufficient data for a meta-analysis comparing 
NOAC-ICH and non-OAC-ICH.
Conclusion This meta-analysis confirms, refines and expands findings from prior studies. We provide precise estimates of 
key prognostic factors and outcomes for VKA-ICH, which has larger haematoma volume, increased rate of HE and higher 
mortality compared to non-OAC ICH. There are insufficient data on NOACs.
Keywords Oral anticoagulants · Intracerebral haemorrhage · Haematoma volume · Mortality · Haematoma expansion
Background
Intracerebral haemorrhage (ICH) is a devastating form of 
stroke with high mortality and morbidity [1]. Oral antico-
agulants (OAC) are beneficial in the prevention of ischaemic 
stroke and systemic embolism in patients with atrial fibrilla-
tion. Vitamin K antagonists (VKA) were the only option for 
OAC therapy for many years, but since 2010, direct throm-
bin inhibitors [2] (dabigatran) and factor Xa inhibitors [3] 
(apixaban, edoxaban and rivaroxaban)—termed non-vitamin 
K antagonist oral anticoagulants (NOAC)—have emerged as 
an alternative option.
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Current knowledge about the influence of OAC on hae-
matoma volume, secondary haematoma expansion (HE) and 
mortality in ICH is mainly based on data from small single 
centre studies conducted in the 1990s [4, 5] or early 2000s 
[6–8]. These studies found that ICH in patients on VKA 
therapy (VKA-ICH) was associated with larger haematoma 
volume and higher rates of HE and mortality compared to 
patients not taking OAC (non-OAC ICH). By contrast, more 
recent studies were less consistent regarding the influence 
of VKA: some did not find differences in ICH volume [7, 
9, 10], HE [9, 10] or mortality [9]; others found that VKA 
influences haematoma volume in non-lobar but not lobar 
ICH location [11], or if the INR was supratherapeutic (>3.0) 
[12].
Since the introduction of NOACs, several single-center 
[13, 14] and multi-center [15–17] studies analysed differ-
ences between VKA-ICH and ICH in patients on NOAC 
therapy (NOAC-ICH) with heterogeneous results.
We conducted a systematic review and meta-analysis of 
published studies to determine the most precise available 
estimates of age, haematoma volume, risk of HE and mor-
tality for OAC-ICH (VKA-ICH or NOAC-ICH) compared 
to non-OAC ICH.
Methods
The report was prepared with respect to the PRISMA 
recommendations [18]. The analysis was performed in 
11/2018–01/2019 according to a pre-planned protocol devel-
oped by all investigators in 10/2018 (not published).
Search strategy and inclusion/exclusion criteria
Two investigators (DJS and MBG) independently searched 
pubmed.gov/MEDLINE for relevant publications on 31 
October 2018 and on 14 November 2018. We used the fol-
lowing search terms: [(oral anticoagulants OR Vitamin K 
antagonists or novel oral anticoagulants or direct oral anti-
coagulants or non-vitamin K antagonist oral anticoagulants) 
and (ICH) AND (mortality or volume)] including different 
spellings and common abbreviations (i.e. VKA, NOAC, 
DOAC, ICH).
We applied the following inclusion criteria:
– Original studies published in English,
– Comparing OAC-ICH (either VKA-ICH or NOAC-ICH 
or both) with non-OAC ICH.
– Recruiting patients from the same population (hospital-
based or population-based studies).
– Reporting at least one of the following outcomes for both 
types of ICH (OAC-ICH and non-OAC ICH): mortality, 
haematoma volume or HE.
We applied the following exclusion criteria:
– Study with less than 10 participants with OAC-ICH.
– Studies reporting Matched cohorts rather than consecu-
tive patients.
Data collection
Two author (DJS and MBG) independently performed the 
literature research and screened all titles and abstracts for 
eligibility. We read the full text of articles potentially eligi-
ble for inclusion and independently extracted data on study 
design, demographics and outcomes. Disagreements were 
resolved by collegial discussion. We included the following 
outcomes.
(a) ICH volume: mean ICH volume in millilitre (ml) with 
standard deviation (SD); if median and interquartile 
range were provided, we extrapolated the mean and SD 
using a published formula and method [19].
(b) Haematoma expansion (HE), usually defined as hae-
matoma volume increase of + 6 ml or + 33% between 
baseline and follow-up imaging.
(c) Mortality: either in-hospital or 3-month mortality.
VKA was defined as the use of warfarin, phenprocoumon, 
fluindione or acénocoumarol. NOAC was defined as the use 
of apixaban, dabigatran, edoxaban or rivaroxaban.
Risk of bias
Two authors (DJS and MBG) independently assessed study 
quality and risk of bias using the scheme suggested by the 
Cochrane collaboration (“Tool to assess risk of bias in 
cohort studies”).
Statistical analysis
We used Review Manager (RevMan) Version 5.3 (Copen-
hagen: The Nordic Cochrane Centre, The Cochrane Col-
laboration, 2014) statistical program package. Patients with 
VKA-ICH and NOAC-ICH were analysed separately and 
compared with patients with non-OAC ICH.
We used the Mantel–Haenszel random-effects method 
to compare mortality and HE and calculated odds ratios 
(OR) and corresponding 95% confidence intervals (CI). 
ICH volumes as continuous variable were pooled using the 
difference of means comparison based on the mean ICH 
volume reported in each study and the corresponding SD. 
We reported the mean difference of ICH volume (in ml) 
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with corresponding SD. Heterogeneity was assessed using 
 I2 statistics and displayed the results using forest plots.
Results
The literature research identified 226 publications. After 
reading the titles and abstracts/full papers if applicable, 
we included 19 studies (see Table 1): 12 publications from 
observational single-centre studies [4, 5, 7–11, 20–24] 
(all tertiary care centres—two publications from the same 
centre reporting complementary outcome data [7, 8]); six 
observational multi-centre studies [6, 12, 25–28] [one pop-
ulation-based study with two publications [6, 12] report-
ing complementary outcome data and one national US 
Get-with-the-guidelines (GWTG) registry [25]]; and one 
sub-analysis of the placebo arm of a randomized controlled 
trial [29]. If there were multiple publications from the same 
study/centre, this study/centre only contributed data from 
one publication to each outcome. Altogether, the studies 
reported data of 150,270 patients with ICH of whom 16,546 
(11.0%) had VKA-ICH, 4943 (3.3%) had NOAC-ICH and 
128,761(85.7%) had non-OAC ICH. The large US GWTG 
study [25] contributed 141,311 (94.0%) patients but reported 
only outcome data for in-hospital mortality and not for hae-
matoma volume, HE or 3-month mortality. The risk of bias 
for included studies was medium (Table 2). 
VKA‑ICH vs. non‑OAC ICH
Overview
All 19 studies reported data of 16,546 patients with VKA-
ICH. The number of patients with VKA-ICH ranged 
between 21 and 208 patients in single- and multi-centre 
studies, with the GWTG registry reporting data of 15,036 
patients with VKA-ICH. Fourteen of 19 studies recruited 
less than 100 patients with VKA-ICH. Patients with VKA-
ICH were significantly older than patients with non-OAC 
ICH (mean age difference: 5.55 years, 95%CI 4.03–7.07, 
p < 0.0001, I2 = 92%, p < 0.001, supplemental figure).
Haematoma volume
Fourteen studies [4, 7, 9–12, 20–24, 27–29] reported data 
on ICH volume in 981 patients with VKA-ICH compared to 
4583 patients with non-OAC ICH. In 7 studies, haematoma 
volume was measured using the ABC/2 formula [9, 11, 12, 
20, 24], three studies used a planimetric software (ALICE or 
Analyze 10.0) [7, 21, 29]. Specifications of the used imaging 
techniques were provided in four studies [9–12, 24]. Details 
on applied methods considering ICH volume measurement 
are provided in the supplementary table. The mean ICH 
volume ranged from 19.9 ml to 44.8 ml in patients with 
VKA-ICH compared to 13.1 ml to 44.6 ml in non-OAC 
ICH. VKA-ICH was associated with significantly larger 
haematoma volume with a pooled mean volume difference 
of 9.66 ml (95%CI 6.24–13.07 ml, p < 0.00001; I2 = 42%, 
p = 0.05; Fig. 1).
Haematoma expansion
Eight studies [7, 9, 10, 20, 22, 24, 28, 29] reported data 
on HE of 302 patients with VKA-ICH compared to 1944 
patients with non-OAC ICH. Overall, VKA-ICH was asso-
ciated with a significantly increased risk of HE (OR 2.96, 
95%CI 1.74–4.97, p < 0.00001; I2 = 65%, p = 0.005, Fig. 2) 
with a pooled rate of 35.8% compared to 18.9% in patients 
with non-OAC ICH.
Mortality
Fifteen studies reported mortality: eight studies [4, 6, 
21–23, 25, 26, 28] reported in-hospital mortality in 15,803 
VKA-ICH patients compared to 125,434 non-OAC ICH 
patients (of whom the majority were from the GWTG reg-
istry: 15,036 patients with VKA-ICH and 121,357 patients 
with non-OAC ICH). Eight studies [5, 8–10, 20, 23, 28, 
29] reported 3-month mortality in 537 patients with VKA-
ICH compared to 2951 patients with non-OAC ICH. VKA-
ICH was associated with increased in-hospital mortality 
(Fig. 3; VKA-ICH: 32.8% vs. non-OAC ICH: 22.4%; OR 
1.83, 95%CI 1.61–2.07, p < 0.00001, I2 = 20%, p = 0.27) 
and 3-month mortality (Fig. 4; VKA-ICH: 47.1% vs. non-
OAC ICH: 25.5%; OR 2.24, 95%CI 1.52–3.31, p < 0.00001) 
although the data showed significant heterogeneity (I2 = 71%, 
p = 0.001) and more recent studies (i.e. published since 2009 
[9, 20, 28]) and those published 2017 [10, 23] from special-
ized stroke centres showed lower mortality rates than older 
studies [5, 8, 29]. 
NOAC‑ICH vs. non‑OAC ICH
Only 2 studies included patients with NOAC-ICH: one sin-
gle-centre study [10] from a German tertiary hospital (25 
NOAC-ICH patients) and the GWTG registry [25]. The lat-
ter reported only data on in-hospital mortality; thus there 
were insufficient studies to perform a meta-analysis.
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Discussion
This systematic review and meta-analysis provided the 
most precise available estimates on key prognostic factors 
and outcomes for OAC-ICH. Our main findings were that 
compared to non-OAC ICH, VKA-ICH is associated with: 
(1) a higher mean haematoma volume of about 10 ml; (2) 
nearly twice the risk of in-hospital and 3-month mortality; 
and (3) nearly triple the risk of HE. There are insufficient 
data to draw firm conclusions about NOAC-ICH compared 
to non-OAC ICH.
This meta-analysis confirms, refines and expands cur-
rent knowledge on the effect of OAC on ICH derived 
from prior studies. Several studies [4, 5, 12] described 
larger haematoma volumes in patients with VKA-ICH 
while more recent studies found no differences [9, 10] or 
differences only in subgroups of patients [11, 20]. Our 
meta-analysis has clarified and expanded these findings. 
We found that VKA-ICH is associated with significantly 
larger haematoma volumes. The increase of nearly 10 ml 
is clinically significant as haematoma volume is one of the 
most important predictors of poor outcome [30]; indeed, 
a haematoma volume of ≥ 30 ml has been included in the 
ICH-score [31] to predict outcome in ICH.
HE is also an important predictor of poor outcome and 
potential target for treatment [32, 33]. In the presence of 
OAC, it is feared that continuous bleeding leads to more 
and significant HE and rapid reversal of the anticoagu-
lant effect is a widely accepted treatment priority [34–38]. 
The first study [7] reporting increased HE rates found a 
large difference between VKA-ICH (54%) and non-OAC 
ICH (16%). Our meta-analysis confirmed a significantly 
higher rate of HE but our more precise estimate suggests 
that the difference is much smaller than initially reported, 
with HE in 36% of patients with VKA-ICH and 19% in 
patients with non-OAC ICH. Nevertheless, we found het-
erogeneity among studies included in our meta-analysis, 
notably differences between studies from North America 
[7, 22, 29] reporting data from the early 2000s and studies 
from Europe and Asia [9, 10, 20, 24, 28] reporting more 
recent data. Regional differences in anticoagulation rever-
sal strategies although not systematically reported in all 
studies might have played a role. European centres tend to 
use PCC combined with FFP and Vitamin K as first-line 
therapy for VKA reversal [35, 36, 38, 39] while in the US, 
FFP combined with Vitamin K has been the mainstay [7, 
36, 37]. A recent randomized controlled trial found that 
PCC is superior to FFP in rapidly reversing VKA-related 
clotting abnormalities, but this study was underpowered 
to find differences in clinical outcomes [40]. The HE 
rate of 36% in patients with VKA-ICH is in line with the 
results from studies comparing HE between VKA-ICH and 
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Table 2  Risk of bias assessment 
according to the Cochrane ‘Tool 
to Assess Risk of Bias in Cohort 
Studies”
1. Was selection of exposed and non-exposed cohorts drawn from the same population?
2. Can we be confident in the assessment of exposure?
3. Can we be confident that the outcome of interest was not present at start of study?
4. Did the study match exposed and unexposed for all variables that are associated with the outcome of 
interest or did the statistical analysis adjust for these prognostic variables?
5. Can we be confident in the assessment of the presence or absence of prognostic factors?
6. Can we be confident in the assessment of outcome?
7. Was the follow-up of cohorts adequate?
8. Were co-interventions similar between groups?
Ratings: +  + , definitely yes (Low risk of bias); + , probably yes; –, probably no; --, definitely no (high risk 
of bias)
1 2 3 4 5 6 7 8
Radberg et al. [5]  +  +  +  + --  +  +  +  + −  +  + 
Neau et al. [4]  +  +  +  + − −  +  +  +  + 
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Fig. 1  Mean difference of ICH volume in VKA-ICH compared to non-OAC ICH
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NOAC-ICH, which reported HE rates between 34% [16] 
and 37% [17] for patients with VKA-ICH. Another study 
investigating treatment strategies for VKA-ICH reported 
an overall HE rate of 36% in VKA-ICH [35]. Interestingly, 
the latter study found a HE rate of only 18% in VKA-ICH 
patients receiving most aggressive treatment (INR < 1.3 
within 1 h and systolic blood pressure < 160 mmHg within 
4 h) which is about the same rate as we found in non-OAC 
ICH (19%). This might point towards important treatment 
effects in VKA-ICH, suggesting potential normalization of 
HE rates if VKA-ICH is treated aggressively.
Although we found increased mortality in patients with 
VKA-ICH confirming prior research [4, 5, 8], there was sig-
nificant heterogeneity among the published studies. Stud-
ies reporting data from the early 2000s or 1990s had worse 
outcome while more recent studies had less-pronounced 
Fig. 2  Rate of haematoma expansion (HE) in VKA-ICH compared to non-OAC ICH
Fig. 3  In-hospital mortality in VKA-ICH compared to non-OAC ICH
Fig. 4  3-month mortality in VKA-ICH compared to non-OAC ICH
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differences. This might in part be explained by recent 
developments in acute blood pressure treatment (follow-
ing INTERACT-2 [41] published in 2013) and widespread 
introduction of stroke unit care for patients with ICH [42]. 
Patients with VKA-ICH may particularly benefit from rapid 
and aggressive therapies in multi-disciplinary dedicated 
stroke unit teams. An aforementioned study [35] investi-
gating treatment effects in VKA-ICH found the overall in-
hospital mortality in VKA-ICH to be 31% which is in line 
with the findings of our meta-analysis (32.8%). Furthermore, 
in this study, patients receiving rapid blood pressure control 
and anticoagulation reversal had in-hospital mortality as low 
as only 13%, even lower as the 22% that we found in the 
non-OAC ICH group of our meta-analysis. Taken together, 
although our meta-analysis found HE and mortality to be 
higher in VKA-ICH, the heterogeneity of data included 
in our meta-analysis together with data from other studies 
might indicate that intensive treatment can significantly 
mitigate excessive HE and mortality reducing it to a level 
comparable to that of non-OAC ICH.
While many studies investigated differences between 
VKA-ICH and NOAC-ICH [13–17], we identified only 2 
studies comparing NOAC-ICH with non-OAC ICH. Data 
from the US GWTG registry [25] found an increased in-
hospital mortality but did not report data on haematoma vol-
ume, HE or 3-month mortality. The study from Von der Bre-
lie et al. [10] found increased haematoma volume, HE and 
3-month mortality in NOAC-ICH but this study included 
only 25 patients with NOAC-ICH.
Our study has several strengths: 1) combining and pool-
ing data from multiple, independent studies with a large 
number of patients with VKA-ICH, we overcome limitations 
from prior smaller studies, refining and expanding their find-
ings; 2) combining data from older with more recent studies 
allowed to highlight possible improvements in treatment of 
VKA-ICH underlining that further efforts to improve treat-
ment are still important; 3) independent literature research 
and extraction of study data from two investigators reduced 
bias and increased data validity.
Our study has the following limitations: (1) we used 
aggregate observational data which are always prone to 
bias; (2) we were not able to perform multivariate analysis 
accounting for other potential predictors of haematoma vol-
ume, HE and mortality including age (VKA-ICH patients 
were 5 years older), acute treatment (blood pressure con-
trol and anticoagulation reversal) and other factors (e.g. 
comorbidities); (3) we were not able to calculate gender- or 
age-specific results. Furthermore, we did not have access to 
INR results at presentation. (4) Different methods applied to 
assess haematoma volumes have certainly contributed to the 
observed heterogeneity of results and are a source of bias. 
However, these methodological limitations applies to both, 
OAC-ICH and non-OAC-ICH. (5) Even with sophisticated 
measuring techniques, for large haematomas, the magnitude 
of haematoma volume measurement error may exceed the 
threshold used to dichotomize HE in the respective study 
[43]. In our analysis of aggregate data, we were not able to 
correct for this incertitude.
To summarize, this meta-analysis provided precise 
estimates of key prognostic variables and outcomes: we 
showed that VKA-ICH has larger haematoma volume, 
more frequent HE and higher mortality than non-VKA-
ICH. Studies comparing NOAC-ICH and non-OAC ICH 
are scarce and current knowledge on NOAC-ICH is only 
available in relation to the effect of VKA-ICH. Further 
research on the effect of NOAC on these outcomes is 
needed.
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